230 related articles for article (PubMed ID: 26039933)
1. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
Zhang L; Gong F; Zhang F; Ma J; Zhang P; Shen J
Int J Nanomedicine; 2013; 8():1517-24. PubMed ID: 23620667
[TBL] [Abstract][Full Text] [Related]
3. Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
Thapa RK; Choi JY; Poudel BK; Hiep TT; Pathak S; Gupta B; Choi HG; Yong CS; Kim JO
ACS Appl Mater Interfaces; 2015 Sep; 7(36):20360-8. PubMed ID: 26315487
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
Liu Y; Feng L; Liu T; Zhang L; Yao Y; Yu D; Wang L; Zhang N
Nanoscale; 2014 Mar; 6(6):3231-42. PubMed ID: 24500240
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Bondì ML; Botto C; Amore E; Emma MR; Augello G; Craparo EF; Cervello M
Int J Pharm; 2015 Sep; 493(1-2):75-85. PubMed ID: 26211902
[TBL] [Abstract][Full Text] [Related]
6. Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
Tom G; Philip S; Isaac R; Praseetha PK; Jiji SG; Asha VV
Life Sci; 2018 Aug; 206():10-21. PubMed ID: 29709652
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
[TBL] [Abstract][Full Text] [Related]
8. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
9. Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
Park W; Chen J; Cho S; Park SJ; Larson AC; Na K; Kim DH
ACS Appl Mater Interfaces; 2016 May; 8(20):12711-9. PubMed ID: 27159350
[TBL] [Abstract][Full Text] [Related]
10. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
11. Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
Li YJ; Dong M; Kong FM; Zhou JP
Int J Pharm; 2015 Jul; 489(1-2):83-90. PubMed ID: 25888801
[TBL] [Abstract][Full Text] [Related]
12. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
13. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
[TBL] [Abstract][Full Text] [Related]
14. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
[TBL] [Abstract][Full Text] [Related]
15. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
Zhang J; Wang T; Mu S; Olerile LD; Yu X; Zhang N
Nanomedicine (Lond); 2017 Apr; 12(8):911-925. PubMed ID: 28339312
[TBL] [Abstract][Full Text] [Related]
16. Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats.
Wang H; Wang H; Yang W; Yu M; Sun S; Xie B
AAPS PharmSciTech; 2018 Feb; 19(2):761-768. PubMed ID: 28983849
[TBL] [Abstract][Full Text] [Related]
17. Magnetically responsive, sorafenib loaded alginate microspheres for hepatocellular carcinoma treatment.
Alpdemir Ş; Vural T; Kara G; Bayram C; Haberal E; Denkbaş EB
IET Nanobiotechnol; 2020 Sep; 14(7):617-622. PubMed ID: 33010138
[TBL] [Abstract][Full Text] [Related]
18. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Tunki L; Kulhari H; Vadithe LN; Kuncha M; Bhargava S; Pooja D; Sistla R
Eur J Pharm Sci; 2019 Sep; 137():104978. PubMed ID: 31254645
[TBL] [Abstract][Full Text] [Related]
19. Nutlin-loaded magnetic solid lipid nanoparticles for targeted glioblastoma treatment.
Grillone A; Battaglini M; Moscato S; Mattii L; de Julián Fernández C; Scarpellini A; Giorgi M; Sinibaldi E; Ciofani G
Nanomedicine (Lond); 2019 Mar; 14(6):727-752. PubMed ID: 30574827
[TBL] [Abstract][Full Text] [Related]
20. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
